





PERSONAL INFORMATION	Alberto Aimo
	 Via Carlo Cattaneo 105, 56125 Pisa (Italy)
	 +39 050883111  +39 3477084391
	 a.aimo@santannapisa.it , aimoalb@ftgm.it
	Gender M Date of birth March 12, 1990 Nationality Italian

POSITION	Research Fellow, Scuola Superiore Sant'Anna, Pisa, Italy
QUALIFICATION	Medicine and Surgery Degree (July 2015); PhD in Translational Medicine (September 2022)
POSITION	Cardiologist, Fondazione Toscana Gabriele Monasterio (FTGM)
QUALIFICATION	Cardiology Degree, University Hospital of Pisa (November 2020)

EDUCATION AND TRAINING	
2016-2020	Resident in Cardiology, University Hospital of Pisa
2013-2016	Internship at the FTGM – clinical and research activity
2009-2016	Internship, Medicine section. Scuola Superiore Sant'Anna, Pisa
2009-2015	Medical School, University of Pisa
2004-2009	Classic High School “Beccaria-Govone” – Mondovì (CN)

PERSONAL SKILLS	
------------------------	--

Mother tongue	Italian				
Other languages	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	C2	C2	C2	C2	C2
French	C1	C1	C1	C1	C1
Spanish	B2	B2	B2	B2	B2

Communication skills	Good communication skills, good teamworking skills
Organisational / managerial skills	Good organisational / managerial skills
Technical skills and competences	<ul style="list-style-type: none"> - American Heart Association (AHA) Basic Life Support Course Pisa, September 2021 - AHA Advanced Cardiovascular Life Support course Pisa, December 2020
Computer skills	European computer driving licence (ECDL)
Certifications	Level 2 cardiac magnetic resonance certification (EACVI)
OTHER INFORMATION	
Publications	<p>Publications: 211 Sum of times cited: 2,154 Citing articles: 1,725 H-index: 23 (Source: Scopus)</p> <p><u>Heart failure and cardiomyopathies</u></p> <p>Rapezzi C, Aimo A, Barison A, et al. Restrictive cardiomyopathy: definition and diagnosis. Eur Heart J. 2022;ehac543.</p> <p>Morfino P, Aimo A, Castiglione V, Gálvez-Montón C, Emdin M, Bayes-Genis A. Treatment of cardiac fibrosis: from neuro-hormonal inhibitors to CAR-T cell therapy. Heart Fail Rev. 2022;1-15. doi:10.1007/s10741-022-10279-x</p> <p>Georgiopoulos G, Delialis D, Aimo A. Inflammation in heart failure: causal determinant or bystander? J Cardiovasc Med. 2022;23:736-737.</p> <p>Bayes-Genis A, Aimo A, Jhund P, et al. Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2022 Sep 8. doi: 10.1002/ejhf.2675. Epub ahead of print.</p>

Morfino P, **Aimo A**, Castiglione V, Vergaro G, Emdin M, Clerico A. Biomarkers of HFpEF: natriuretic peptides, high-sensitivity troponins and beyond. *J Cardiovasc Dev Dis*. 2022;9:256.

Aimo A, Lupon J, Spitaleri G, et al. Global warming, renal function and heart failure over 20 years. *Int J Cardiol*. 2022 Aug 1:S0167-5273(22)01113-5. Epub ahead of print.

Chianca M, Panichella G, Fabiani I, ... **Aimo A**, et al. Bidirectional relationship between cancer and heart failure: insights on circulating biomarkers. *Front Cardiovasc Med*. 2022;9:936654.

Aimo A, Castiglione V, Bayes-Genis A. Do we need to EVALUATE multiple biomarkers and/or the same biomarkers multiple times in patients with heart failure? *Eur J Heart Fail*. 2022;10.1002/ejhf.2580.

Bayes-Genis A, **Aimo A**, Lupón J. Empagliflozin in HFpEF/HFmrEF: prognostic benefit confirmed with different endpoint definitions. *Eur J Heart Fail*. 2022;10.1002/ejhf.2597.

Bayés-Genís A, **Aimo A**, Metra M, et al. Head-to-head comparison between recommendations by the ESC and ACC/AHA/HFSA heart failure guidelines. *Eur J Heart Fail*. 2022 May 17. Epub ahead of print.

Aimo A, Senni M, Barison A, et al. Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin. *Heart Fail Rev*. 2022 Apr 29. Epub ahead of print.

González A, Richards AM, de Boer RA, ... **Aimo A**, et al. Cardiac remodelling Part 1: from cells and tissues to circulating biomarkers. *Eur J Heart Fail*. 2022 Mar 25 (Epub ahead of print).

Aimo A, Vergaro G, González A, et al. Cardiac remodelling Part 2: Clinical, Imaging and Laboratory Findings. A review from the Biomarkers Working Group of the Heart Failure Association of the ESC. *Eur J Heart Fail* 2022 (in press).

Emdin M, **Aimo A**, Castiglione V. Is targeting cyclic guanosine monophosphate by vericiguat effective to treat ischaemic heart failure with reduced ejection fraction? Yes, it is. *Eur J Heart Fail*. 2022;24:791-793.

Aimo A, Georgiopoulos G, Panichella G, et al. High-sensitivity troponins for outcome prediction in the general population: a systematic review and meta-analysis. *Eur J Intern Med*. 2022;98:61-68.

Vergaro G, Gentile F, **Aimo A**, et al. Circulating levels and prognostic cut-offs of sST2, hs-cTnT, and NT-proBNP in women vs. men with chronic heart failure. *ESC Heart Fail*. 2022 May 5. Epub ahead of print.

Aimo A, Lupón J, Bayes-Genis A, Emdin M. Urinary NGAL in acute heart failure revisited: the game is not over yet. *Int J Cardiol*. 2022:S0167-5273(22)00382-5.

Pagnesi M, Baldetti L, **Aimo A**, et al. Prognostic benefit of new drugs for HFrEF: a systematic review and network meta-analysis. *J Clin Med*. 2022;11:348.

Vergaro G, **Aimo A**, Januzzi JL, et al. Cardiac biomarkers retain prognostic significance in patients with heart failure and COPD. *J Cardiovasc Med*. 2021 (in press).

Gentile F, **Aimo A**, Passino C, Emdin M, Vergaro G. Reply: natriuretic peptide-based risk prediction and assessment of treatment effect: revisited in this era. *JACC Heart Fail*. 2021;9:942-943.

Moura B, **Aimo A**, Al-Mohammad A, et al. Integration of imaging and circulating biomarkers in heart failure: a consensus document by the Biomarkers and Imaging Study Groups of the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail.* 2021;23:1577-1596.

Lombardi CM, Cimino G, Pagnesi M, ...**Aimo A**. Vericiguat for heart failure with reduced ejection fraction. *Curr Cardiol Rep.* 2021;23:144.

Gentile F, Sciarrone P, Zamora E, ... **Aimo A**, et al. Body mass index and outcomes in ischaemic versus non-ischaemic heart failure across the spectrum of ejection fraction. *Eur J Prev Cardiol.* 2021;28:948-955.

Aimo A, Saccaro LF, Borrelli C, et al. The ergoreflex: how the skeletal muscle modulates ventilation and cardiovascular function in health and disease. *Eur J Heart Fail.* 2021 Jul 16. Epub ahead of print.

Fabiani I, Panichella G, **Aimo A**, et al. Subclinical cardiac damage in cancer patients before chemotherapy. *Heart Fail Rev.* 2021 Jul 27. Epub ahead of print.

Aimo A, Panichella G, Barison A, et al. Sex-related differences in ventricular remodeling after myocardial infarction. *Int J Cardiol.* 2021:S0167-5273(21)01181-5.

Vergaro G, Gentile F, Meems LMG, **Aimo A**, et al. NT-proBNP for risk prediction in heart failure: identification of optimal cutoffs across body mass index categories. *JACC Heart Fail.* 2021:S2213-1779(21)00271-7.

Ghionzoli N, Gentile F, Del Franco AM, ...**Aimo A**, et al. Current and emerging drug targets in heart failure treatment. *Heart Fail Rev.* 2021 Jul 17. Epub ahead of print.

Barison A, **Aimo A**. Digoxin use in patients with cardiovascular diseases: An old remedy for future medicine? *Int J Cardiol.* 2021:S0167-5273(21)01171-2.

Aimo A, Castiglione V, Vergaro G, et al. The place of vericiguat in the current landscape of heart failure treatment. *Heart Fail Rev.* 2021 Jul 21. Online ahead of print.

Aimo A, Vergaro G, Passino C, Clerico A. Evaluation of pathophysiological relationships between renin-angiotensin and ACE-ACE2 systems in cardiovascular disorders: from theory to routine clinical practice in patients with heart failure. *Crit Rev Clin Lab Sci.* 2021:1-16.

Clerico A, **Aimo A**, Zaninotto M, Plebani M. Transdermal measurement of cardiac troponins: the future is now. *Clin Chem Lab Med.* 2022 May 5. Epub ahead of print.

Aimo A. Longitudinal changes in cardiac biomarkers and outcome in heart failure: Sex-related differences. *Int J Cardiol.* 2021;336:84-85.

Vergaro G, Castiglione V, **Aimo A**, et al. Biomarcatori per la diagnosi e la gestione dello scompenso cardiaco: nuove frontiere [Biomarkers for the diagnosis and management of heart failure: new frontiers]. *G Ital Cardiol (Rome).* 2021;22:386-396.

Vergaro G, **Aimo A**, Taurino E, et al. Discharge FGF23 level predicts one year outcome in patients admitted with acute heart failure. *Int J Cardiol.* 2021;336:98-104.

Aimo A, Fabiani I, Vergaro G, et al. Prognostic value of reverse remodelling criteria in heart failure with reduced or mid-range ejection fraction. *ESC Heart Failure.* 2021 (in press).

Aimo A, Pateras K, Stamatelopoulos K, et al. Relative efficacy of sacubitril-valsartan, vericiguat, and SGLT2 inhibitors in heart failure with reduced ejection fraction: a systematic review and network meta-analysis. *Cardiovasc Drugs Ther.* 2020 Oct 19. Epub ahead of print.

Emdin M, **Aimo A**, Castiglione V, et al. Targeting cyclic guanosine monophosphate to treat heart failure: JACC Review Topic of the Week. *J Am Coll Cardiol.* 2020;76:1795-1807.

Gimelli A, **Aimo A**, Pasanisi EM, et al. Myocardial stress perfusion scintigraphy for outcome prediction in patients with severe left ventricular systolic dysfunction. *Eur J Nucl Med Mol Imaging.* 2021 Mar 18. Epub ahead of print.

Núñez J, Núñez E, Revuelta-López E, et al. The influence of sex and body mass index on the association between soluble neprilysin and risk of heart failure hospitalizations. *Sci Rep.* 2021;11:5940.

Georgiopoulos G, Zampieri M, Molaro S, ...**Aimo A**, et al. Cardiac magnetic resonance in patients with ARVC and family members: the potential role of native T1 mapping. *Int J Cardiovasc Imaging.* 2021 Feb 7. Epub ahead of print.

Clerico A, **Aimo A**, Passino C. The pathophysiological and clinical relevance of combined measurement of natriuretic peptides and cardiac troponins for risk prediction of incident heart failure in community-dwelling individuals. *Eur J Heart Fail.* 2021 Feb 2. Epub ahead of print.

Georgiopoulos G, **Aimo A**, Barison A, et al. Imaging predictors of incident heart failure: a systematic review and meta-analysis. *J Cardiovasc Med (Hagerstown).* 2021;22:378-387.

Castiglione V, **Aimo A**, Vergaro G, et al. Biomarkers for the diagnosis and management of heart failure. *Heart Fail Rev.* 2021 Apr 14. Epub ahead of print. PMID: 33852110.

Aimo A, Prontera C, Passino C, Emdin M, Vergaro G. Norepinephrine, plasma renin activity and cardiovascular mortality in systolic heart failure. *Heart.* 2021:heartjnl-2020-318791.

Marcks N, **Aimo A**, Januzzi JL Jr, et al. Re-appraisal of the obesity paradox in heart failure: a meta-analysis of individual data. *Clin Res Cardiol.* 2021 Mar 11. Epub ahead of print.

Barison A, **Aimo A**, Emdin M. Cocaine and methamphetamine use and hospitalization for acute heart failure: Epidemiological evidence from a nationwide dataset. *Int J Cardiol.* 2021:S0167-5273(21)00387-9.

Aimo A, Pelliccia F, Panichella G, et al. Indications of beta-adrenoceptor blockers in Takotsubo syndrome and theoretical reasons to prefer agents with vasodilating activity. *Int J Cardiol.* 2021:S0167-5273(21)00385-5.

Castiglione V, Vergaro G, **Aimo A**, et al. Biomarcatori per la diagnosi e la gestione dello scompenso cardiaco: i peptidi natriuretici [Biomarkers for the diagnosis and management of heart failure: natriuretic peptides]. *G Ital Cardiol (Rome).* 2021;22:292-300.

Aimo A, Valleggi A, Barison A, et al. Morphologies and prognostic significance of left ventricular volume/time curves with cardiac magnetic resonance in patients with non-ischaemic heart failure and left bundle branch block. *Int J Cardiovasc Imaging.* 2021 Feb 26. Epub ahead of print.

Aimo A, Pateras K, Stamatelopoulos K, et al. Relative efficacy of sacubitril-valsartan, vericiguat, and SGLT2 inhibitors in heart failure

with reduced ejection fraction: a systematic review and network meta-analysis. *Cardiovasc Drugs Ther.* 2020 Oct 19 [Epub ahead of print].

Emdin M, **Aimo A**, Castiglione V, et al. Targeting cyclic guanosine monophosphate to treat heart failure: the long journey from nitrates to vericiguat: JACC Review Topic of the Week. *JACC* 2020 [in press].

Gentile F, Sciarrone P, Zamora E, ...**Aimo A**, et al. Body mass index and outcomes in ischaemic versus non-ischaemic heart failure across the spectrum of ejection fraction. *Eur J Prev Cardiol.* 2020 [online ahead of print].

Barison A, **Aimo A**, Mirizzi G, et al. The extent and location of late gadolinium enhancement predict defibrillator shock and cardiac mortality in patients with non-ischaemic dilated cardiomyopathy. *Int J Cardiol.* 2020;307:180-186.

Aimo A, Castiglione V, Lombardi CM. Effects of vericiguat in heart failure with reduced ejection fraction: do not forget sST2. *Eur J Heart Fail.* 2020 [online ahead of print].

Aimo A, Januzzi JL, Vergaro G, et al. Circulating levels and prognostic value of sST2 in heart failure are less influenced by age than NT-proBNP and high-sensitivity troponin T. *Eur J Heart Fail.* 2020 [online ahead of print].

Aimo A, Januzzi JL, Bayes-Genis A, et al. Clinical and prognostic significance of sST2 in heart failure: JACC Review Topic of the Week. *J Am Coll Cardiol.* 2019;74:2193-2203.

Aimo A, Tavoni A, Buda G, Emdin M. Rituximab as a novel treatment for heart failure: evidence from a case series. *Eur Heart J Case Rep.* 2019;3:1-2.

Aimo A, Georgiopoulos G, Senni M, Emdin M. Searching for diagnostic biomarkers of HFpEF: methodological issues. *Eur J Heart Fail.* 2020;22:1598-1599.

Barison A, **Aimo A**, Todiere G, et al. Cardiovascular magnetic resonance for the diagnosis and management of heart failure with preserved ejection fraction. *Heart Fail Rev.* 2020 [online ahead of print]

Aimo A, Castiglione V, Borrelli C, et al. Oxidative stress and inflammation in the evolution of heart failure: From pathophysiology to therapeutic strategies. *Eur J Prev Cardiol.* 2020;27:494-510.

Aimo A, Maisel AS, Castiglione V, Emdin M. sST2 for outcome prediction in acute heart failure: which is the best cutoff? *J Am Coll Cardiol.* 2019;74:478-479.

Aimo A, Januzzi JL Jr, Vergaro G, et al. Revisiting the obesity paradox in heart failure: percent body fat as predictor of biomarkers and outcome. *Eur J Prevent Cardiol.* 2019;26:1751-1759.

Emdin M, **Aimo A**, Poletti R, Bayes-Genis A. Targeting social disadvantage to prevent early development of heart failure. *Int J Cardiol.* 2019;293:181-182.

Aimo A, Gaggin HK, Barison A, et al. Predictors of cardiac remodeling in heart failure with reduced ejection fraction and role of biomarkers. *JACC Heart Fail.* 2019;7:782-794.

Vergaro G, **Aimo A**, Emdin M, Zareba W. The ST2-SCD score and the conundrum of sudden death prediction in heart failure. *Int J Cardiol.* 2019;294:50-51.

Aimo A, Januzzi JL, Mueller C, et al. Admission high-sensitivity troponin T and NT-proBNP for outcome prediction in acute heart failure. *Int J Cardiol.* 2019;293:137-142.

Aimo A, Barison A, Castiglione V, Emdin M. The unbearable underreporting of comorbidities in heart failure clinical trials. *Eur J Heart Fail.* 2020;22:1043-1044.

Aimo A, Vergaro G, Emdin M. The importance of being frail: a score to predict frailty of patients hospitalized for heart failure. *Int J Cardiol.* 2020 [online ahead of print].

Vergaro G, **Aimo A**, Prontera C, et al. Sympathetic and renin-angiotensin-aldosterone system activation in heart failure with preserved, mid-range and reduced ejection fraction. *Int J Cardiol.* 2019;296:91-97.

Aimo A, Emdin M, Maisel AS. Sacubitril/valsartan, cardiac fibrosis and remodeling in heart failure. *JACC.* 2019;73:3038-3039.

Emdin M, **Aimo A**, Clerico A, Januzzi JL. Race/ethnicity and plasma NT-proBNP in black and white individuals: How it matters. *Int J Cardiol.* 2019;286:164-165.

Aimo A, Vergaro G, Cohen Solal A, Emdin M. Relative hypochromia in acute heart failure to predict outcome and guide treatment: Ready for prime time? *Int J Cardiol.* 2019;286:111-112.

Aimo A, Januzzi JL Jr, Vergaro G, et al. High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure. *Int J Cardiol.* 2019;277:166-172.

Emdin M, **Aimo A**, Vergaro G, et al. sST2 predicts outcome in chronic heart failure beyond NT-proBNP and high sensitivity troponin T. *JACC*. 2018;72:2309-2320.

Aimo A, Januzzi JL Jr, Vergaro G, et al. Left ventricular ejection fraction for risk stratification in chronic systolic heart failure. *Int J Cardiol*. 2018;273:136-140.

Aimo A, Seghieri C, Nuti S, Emdin M. Building medical knowledge from real world registries: The case of heart failure. *Int J Cardiol Heart Vasc*. 2018;19:98-99.

Emdin M, **Aimo A**, Mirizzi G, Piacenti M. Is fat good for arrhythmias in ischemic heart failure? Another face of the obesity paradox. *Int J Cardiol*. 2018;265:169-170.

Passino C, **Aimo A**, Emdin M, Vergaro G. Quality of life and outcome in heart failure with preserved ejection fraction: When sex matters. *Int J Cardiol*. 2018;267:141-142.

Aimo A, Ripoli A, De Caterina R, Emdin M. Aspirin and prognosis in heart failure: a question of power. *JACC HF*. 2018;6:538-539.

Aimo A, Vergaro G, Emdin M. High-sensitivity troponins and prognosis in heart failure: which kind of meta-analysis is needed? *JACC HF*. 2018;6:440-441.

Aimo A, Vergaro G, Giannoni A, Emdin M. Wet is bad: Residual congestion predicts worse prognosis in acute heart failure. *Int J Cardiol*. 2018;258:201-202.

Vergaro G, **Aimo A**, Barison A, Emdin M. A mechanistic look at sacubitril/valsartan action. Unravelling magician's secrets. *Int J Cardiol.* 2018;258:203-204.

Arzilli C, **Aimo A**, Vergaro G, et al. N-terminal fraction of pro-B-type natriuretic peptide versus clinical risk scores for prognostic stratification in chronic systolic heart failure. *Eur J Prev Cardiol.* 2018;25:889-895.

Aimo A, Januzzi JL Jr, Vergaro G, et al. Prognostic value of high-sensitivity troponin T in chronic heart failure: an individual patient data meta-analysis. *Circulation.* 2018;137:286-297.

Aimo A, Vergaro G, Barison A, et al. Sex-related differences in chronic heart failure. *Int J Cardiol.* 2018;255:145-151.

Emdin M, **Aimo A**, Vergaro G, Pastormerlo LE, Clerico A. Natriuretic peptides. D'où venons-nous? Que sommes-nous? Où allons-nous? *Int J Cardiol.* 2018;254:256-257.

Passino C, **Aimo A**, Mirizzi G, Emdin M. Exercise intolerance in heart failure with preserved ejection fraction: A reappraisal of central mechanisms? *Int J Cardiol.* 2018;254:248-249.

Emdin M, **Aimo A**, Gabutti A, Giannoni A. Underprescription of disease-modifying drugs in chronic heart failure: More is better? *Int J Cardiol.* 2018;254:242-243.

Aimo A, Barison A, Mammini C, Emdin M. The Barthel Index in elderly acute heart failure patients. Frailty matters. *Int J Cardiol.* 2018;254:240-241.

Vergaro G, **Aimo A**, Passino C, Emdin M. Heart, kidney and FGF23: Les liaisons dangereuses. *Int J Cardiol.* 2018;253:120-121.

Emdin M, **Aimo A**, Passino C, Giannoni A. Noncardiovascular death after acute heart failure. Do not lose the war while fighting for the failing heart. *Int J Cardiol.* 2018;250:231-232.

Barison A, **Aimo A**, Ortalda A, et al. Late gadolinium enhancement as a predictor of functional recovery, need for defibrillator implantation and prognosis in non-ischemic dilated cardiomyopathy. *Int J Cardiol.* 2018;250:195-200.

Aimo A, Vergaro G, Castiglione V, et al. Effect of sex on reverse remodeling in chronic systolic heart failure. *JACC HF.* 2017;5:735-742.

Borrelli C, **Aimo A**, Mirizzi G, et al. How to take arms against central apneas in heart failure. *Expert Rev Cardiovasc Ther.* 2017;15:743-755.

Emdin M, **Aimo A**, Passino C, Vergaro G. Breathing Not Properly in the oldest old. Is brain natriuretic peptide a poor test for the diagnosis of heart failure in the elderly? *Eur J Heart Fail.* 2017;19:549-551.

Aspromonte N, Gulizia MM, Clerico A, ... **Aimo A**, et al. ANMCO/ELAS/SIBioC Consensus Document: biomarkers in heart failure. *Eur Heart J Suppl.* 2017;19:D102–D112.

Aspromonte N, Gulizia MM, Clerico A, ... **Aimo A**, Ciaccio M, Migliardi M. [ANMCO/ELAS/SIBioC Consensus document: Recommendations for the use of cardiac biomarkers in heart failure patients]. *G Ital Cardiol (Rome).* 2016;17:615-656.

Emdin M, **Aimo A**, Vergaro G, Passino C. Predicting readmissions after hospitalization for heart failure: Medical reasoning vs calculators. *Int J Cardiol.* 2017;236:348-349.

Aimo A, Vergaro G, Ripoli A, et al. Meta-analysis of soluble suppression of tumorigenicity-2 and prognosis in acute heart failure: a meta-analysis. *JACC Heart Fail.* 2017;5:287-296.

Aimo A, Vergaro G, Passino C, et al. Prognostic value of soluble suppression of tumorigenicity-2 (sST2) in chronic heart failure: a meta-analysis. *JACC Heart Fail.* 2017;5:280-286.

Padeletti L, **Aimo A**, Vishnevsky B, et al. The prognostic benefit of cardiac resynchronization therapy is greater in concordant vs. discordant left bundle branch block in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). *Europace.* 2018;20:794-800.

Passino C, **Aimo A**, Emdin M. Consensus Document of the National Association of Clinical Cardiologists (Associazione Nazionale Medici Cardiologi Ospedalieri, ANMCO): Raccomandazioni sull'impiego dei biomarcatori cardiaci nello scompenso cardiaco. Attuali Linee Guida sullo scompenso cardiaco [article in Italian]. *G Ital Cardiol.* 2016;17.

Aimo A, Borrelli C, Vergaro G, et al. Targeting mitochondrial dysfunction in chronic heart failure: current evidence and potential approaches. *Curr Pharm Design.* 2016;22:4807-22.

Giannoni A, Mirizzi G, **Aimo A**, Emdin M, Passino C. Peripheral feedback in heart failure: is it time for a direct treatment? *World J Cardiol.* 2015;7:824-828.

Aimo A, Giannoni A, Piepoli MF, et al. Myocardial damage in a mitochondrial myopathy patient with increased ergoreceptor sensitivity and sympatho-vagal imbalance. *Int J Cardiol.* 2014;176:1396-8.

Giannoni A, Raglianti V, Mirizzi G, ...**Aimo A**, et al. Influence of central apneas and chemoreflex activation on pulmonary artery pressure in chronic heart failure. *Int J Cardiol.* 2016;202:200-206.

Giannoni A, Passino C, Mirizzi G, Del Franco A, **Aimo A**, Emdin M. Treating chemoreflex in heart failure: modulation or demolition? *J Physiol.* 2014;592:1903-4.

Aimo A, Bianchi G, Vergaro G. Integrated imaging to investigate low-flow alarms of left ventricular assist devices. *JACC Case Reports.* 2020 [in press].

Cardiac amyloidosis

Turco S, Lazzari J, Manetti AC, ... **Aimo A**... Death occurred due to undiagnosed systemic amyloidosis: a case report. *Clin Ter.* 2022;173:516-519. doi:10.7417/CT.2022.2473

Rapezzi C, Emdin M, **Aimo A**. Unravelling the role of sex in the pathophysiology, phenotypic expression and diagnosis of cardiac amyloidosis. *Eur J Heart Fail.* 2022;10.1002/ejhf.2674.

Sanguinetti C, Minniti M, Susini V, Caponi L, Panichella G, Castiglione V, **Aimo A**, Emdin M, Vergaro G, Franzini M. The journey of human transthyretin: synthesis, structure stability, and catabolism. *Biomedicines.* 2022;10:1906.

Tomasoni D, **Aimo A**, Merlo M, et al. Value of the HFA-PEFF and H₂FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis. *Eur J Heart Fail.* 2022 Jul 20. Epub ahead of print.

Vergaro G, **Aimo A**, Rapezzi C, et al. Atrial amyloidosis: mechanisms and clinical manifestations. *Eur J Heart Fail*. 2022 Aug 3. Epub ahead of print.

Vergaro G, **Aimo A**, Castiglione V, Emdin M. Stroke in ATTR cardiac amyloidosis: Does only rhythm matter? *Int J Cardiol*. 2022;S0167-5273(22)00945-7.

Rapezzi C, Serenelli M, **Aimo A**. Early-stage amyloid transthyretin cardiomyopathy: uncertainties and opportunities. *Eur Heart J*. 2022 May 26:e hac261.

Aimo A, Merlo M, Porcari A, Georgiopoulos G, Pagura L, Vergaro G, Sinagra G, Emdin M, Rapezzi C. Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies. *Eur J Heart Fail*. 2022 May 4. Epub ahead of print.

Aimo A, Fabiani I, Giannoni A, et al. Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis. *Eur Heart J Cardiovasc Imaging*. 2022 Mar 16 (Epub ahead of print).

Aimo A, Castiglione V, Rapezzi C, et al. RNA-targeting and gene editing therapies for transthyretin amyloidosis. *Nat Rev Cardiol*. 2022 Mar 23 (Epub ahead of print).

Rapezzi C, Vergaro G, Emdin M, ... **Aimo A**. The revolution of ATTR amyloidosis in cardiology: certainties, gray zones and perspectives. *Minerva Cardiol Angiol*. 2022;70:248-257.

Morfino P, **Aimo A**, Panichella G, Rapezzi C, Emdin M. Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis. *Heart Fail Rev*. 2022;27:2187-2200.

Rapezzi C, **Aimo A**, Serenelli M, et al. Critical comparison of documents from scientific societies on cardiac amyloidosis: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2022;79:1288-1303.

Vergaro G, **Aimo A**, Campora A, et al. Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure. *Amyloid*. 2021:1-7.

Rapezzi C, **Aimo A**, Pavasini R. Longitudinal strain in the management of cardiac AL amyloidosis: do we need it? *Eur Heart J*. 2021 Sep 9:ehab609.

Nicol M, Siguret V, Vergaro G, **Aimo A**, et al. Thromboembolism and bleeding in systemic amyloidosis: a review. *ESC Heart Fail*. 2021 Nov 16. Epub ahead of print.

Pucci A, **Aimo A**, Musetti V, et al. Amyloid deposits and fibrosis on left ventricular endomyocardial biopsy correlate with extracellular volume in cardiac amyloidosis. *J Am Heart Assoc*. 2021;10(20):e020358.

Vergaro G, **Aimo A**, Campora A, et al. Sympathetic and renin-angiotensin-aldosterone system activation in patients with cardiac amyloidosis. *Amyloid*. 2021 [in press].

Aimo A, Castiglione V, Barison A, Chubuchnyi V, Emdin M. The left ventricular mass-to-strain ratio: enough to differentiate ATTR from AL cardiac amyloidosis? *JACC Cardiovasc Imaging*. 2021;14:1877-1878.

Emdin M, Perfetto F, **Aimo A**, et al. Percorso clinico-assistenziale in rete per la diagnosi e la gestione del paziente con amiloidosi cardiaca. Documento di consenso ANMCO Toscana e SIC Tosco-Umbra [Approach to the diagnosis and management of patients with cardiac amyloidosis. A consensus document by the Tuscan section of the Italian

Association of Hospital Cardiologists (ANMCO) and the Tusco-Umbrian section of the Italian Society of Cardiology (SIC)]. *G Ital Cardiol (Rome)*. 2021;22:621-634.

Aimo A, Rapezzi C, Perfetto F, et al. Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis. *Eur J Clin Invest*. 2021:e13598.

Aimo A. Response to the comment by Dr. Yarlas. *Eur J Clin Invest*. 2021 Jul 22:e13652.

Martini N, **Aimo A**, Barison A, et al. Deep learning to diagnose cardiac amyloidosis from cardiovascular magnetic resonance. *J Cardiovasc Magn Reson*. 2020;22:84.

Aimo A, Rapezzi C, Arzilli C, Vergaro G, Emdin M. Safety and efficacy of levosimendan in patients with cardiac amyloidosis. *Eur J Intern Med*. 2020;80:114-116.

Aimo A, Vergaro G, Castiglione V, Rapezzi C, Emdin M. Safety and tolerability of neurohormonal antagonism in cardiac amyloidosis. *Eur J Intern Med*. 2020;80:66-72.

Vergaro G, Castiglione V, Poletti R, ...**Aimo A**, et al. Biopsy evidence of sequential transthyretin and immunoglobulin light-chain cardiac amyloidosis in the same patient. *JACC Case Rep*. 2021;3:450-454.

Castiglione V, Franzini M, **Aimo A**, et al. Use of biomarkers to diagnose and manage cardiac amyloidosis. *Eur J Heart Fail*. 2021;23:217-230.

Rapezzi C, **Aimo A**, Emdin M. Tafamidis is entering the clinical arena for the treatment of transthyretin-related cardiomyopathy: certainties and unmet needs. *Eur J Heart Fail*. 2021;23:286-289.

Aimo A, Chubuchny V, Vergaro G, et al. A simple echocardiographic score to rule out cardiac amyloidosis. *Eur J Clin Invest*. 2020:e13449.

Barison A, **Aimo A**, Emdin M. Assessing cardiac response to patisiran by changes in extracellular volume: potential issues. *JACC Cardiovasc Imaging*. 2021;14:881-882.

Aimo A, Barison A, Emdin M. Magnetic resonance to diagnose cardiac amyloidosis: is it already time to discard contrast agents? *JACC Cardiovasc Imaging*. 2020;13:1293-1294.

Vergaro G, **Aimo A**, Musetti V, et al. Abdominal fat biopsy for the diagnosis of cardiac amyloidosis. *JACC Case Reports*. 2020;2:1182-1185.

Gimelli A, **Aimo A**, Vergaro G, et al. Cardiac sympathetic denervation in wild-type transthyretin amyloidosis. *Amyloid*. 2020:1-7.

Grigoratos C, **Aimo A**, Rapezzi C, et al. Diphosphonate single-photon emission computed tomography in cardiac transthyretin amyloidosis. *Int J Cardiol*. 2020;307:187-192.

Aimo A, Rapezzi C, Vergaro G, et al. Management of complications of cardiac amyloidosis: 10 questions and answers. *Eur J Prev Cardiol*. 2021;28:1000-1005.

Vergaro G, **Aimo A**, Barison A, et al. Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings. *Eur J Prev Cardiol*. 2020;27:1806-1815.

Emdin M, **Aimo A**, Rapezzi C, et al. Treatment of cardiac transthyretin amyloidosis: an update. *Eur Heart J*. 2019;40:3699-3706.

Boldrini M, Cappelli F, Chacko L, ...**Aimo A**, et al. Multiparametric echocardiography scores for the diagnosis of cardiac amyloidosis. *JACC Cardiovasc Imaging*. 2020;13:909-920.

Aimo A, Buda G, Fontana M, et al. Therapies for cardiac light chain amyloidosis: an update. *Int J Cardiol*. 2018;271:152-160.

Aimo A, Vergaro G, Pucci A, et al. Cardiac light-chain deposition disease relapsing in the transplanted heart. *Amyloid*. 2017;24:135-137.

Grigoratos C, **Aimo A**, Barison A, et al. Cardiac magnetic resonance in patients with muscular dystrophies. *Eur J Prev Cardiol*. 2021;28:1526-1535.

Aimo A, Emdin M. Neurohormonal modulation for treatment of cardiac involvement in dystrophinopathies and mitochondrial disease (reply). *Eur J Prev Cardiol*. 2017;24:1727-1728.

Aimo A, Giannoni A, Castiglione V, et al. Neurohormonal modulation for treatment of cardiac involvement in dystrophinopathies and mitochondrial disease. *Eur J Prev Cardiol*. 2017;24:1718-1724.

Giannoni A, **Aimo A**, Mancuso M, et al. Autonomic, functional, skeletal muscle, and cardiac abnormalities are associated with increased ergoreflex sensitivity in mitochondrial disease. *Eur J Heart Fail*. 2017;19:1701-1709.

Aimo A, Barison A, Emdin M. Letter by Aimo et al. regarding article “Development and validation of a new risk prediction score for life-threatening ventricular tachyarrhythmias in laminopathies” by Wahbi et al. *Circulation*. 2019;140:e816-e817.

Fabiani I, **Aimo A**, Grigoratos C, et al. Oxidative stress and inflammation: determinants of anthracycline cardiotoxicity and possible therapeutic targets. Heart Fail Rev. 2020 Dec 15. Epub ahead of print.

Aimo A, Fabiani I, Emdin M. Evaluating biomarkers as predictors of cancer therapy cardiotoxicity: all you need is a meta-analysis? Eur J Heart Fail. 2020;22:1284-1285.

Aimo A, Di Paolo M, Bevenuti M, et al. Scared to death: acute emotional stress causing fatal myocardial infarction with non-obstructed coronary arteries. A case series. JACC Case Reports. 2020;2:2400-2403.

Castiglione V, **Aimo A**, Aquaro GD, et al. What's hidden behind inferior negative T waves: multiple cardiac glomangiomas. JACC Case Reports. 2019;1:657-662.

Imaging beyond heart failure/cardiomyopathies

Aimo A, Huang L, Tyler A, Barison A, Martini N, Saccaro LF, Roujol S, Masci PG. Quantitative susceptibility mapping (QSM) of the cardiovascular system: challenges and perspectives. J Cardiovasc Magn Reson. 2022;24:48.

Klettas D, Georgiopoulos G, Rizvi Q, ...**Aimo A**, et al. Echocardiographic and cardiac magnetic resonance imaging-derived strains in relation to late gadolinium enhancement in hypertrophic cardiomyopathy. Am J Cardiol. 2022;171:132-139.

Aimo A, Gimelli A. Myocardial innervation imaging: MIBG in clinical practice. Imaging. 2021 (in press).

Aimo A, Kollia E, Ntritsos G, et al. Echocardiography versus computed tomography and cardiac magnetic resonance for the detection of left

heart thrombosis: a systematic review and meta-analysis. *Clin Res Cardiol.* 2021;110:1697-1703.

Aimo A, Gimelli A. The relativity of reference values for myocardial perfusion imaging. *JACC Cardiovasc Imaging.* 2020:S1936-878X(20)30604-5.

Aimo A, Gimelli A. Myocardial perfusion years after radiation therapy for left-sided breast cancer: evidence from a positron emission tomography study. *J Nucl Med.* 2021;28:1933-1935.

Ischemic heart disease

Morrone D, Gentile F, **Aimo A**, et al. Perspectives in noninvasive imaging for chronic coronary syndromes. *Int J Cardiol.* 2022:S0167-5273(22)01108-1.

Iborra-Egea O, **Aimo A**, Bayes-Genis A. Different effects on protein expression of CDR132L, an antisense inhibitor of miR-132, and standard therapies for myocardial infarction. *Front Cardiovasc Med.* 2022;9:887236.

Iborra-Egea O, **Aimo A**, Martini N, et al. The potential anti-remodeling effect of paroxetine after myocardial infarction may be blunted by beta-blockers. *Front Cardiovasc Med.* 2022;9:887248.

Clerico A, Zaninotto M, **Aimo A**, et al. Use of high-sensitivity cardiac troponins in the emergency department for the early rule-in and rule-out of acute myocardial infarction without persistent ST-segment elevation (NSTEMI) in Italy. Expert Opinion Document from the Study Group of Cardiac Biomarkers associated to the Italian Societies ELAS (European Ligand Assay Society, Italy Section), SIBIoC (Società Italiana di Biochimica Clinica), and SIPMeL (Società Italiana di Patologia Clinica e Medicina di Laboratorio). *Clin Chem Lab Med.* 2021 (in press).

Radico F, Di Castelnuovo A, **Aimo A**, et al. Factors for heterogeneous outcomes of angina and myocardial ischemia without obstructive coronary atherosclerosis. *J Intern Med.* 2022;291:197-206.

Aimo A, Chiappino S, Clemente A, et al. The triglyceride/HDL cholesterol ratio and TyG index predict coronary atherosclerosis and outcome in the general population. *Eur J Prev Cardiol.* 2022;29:e203-e204.

Neglia D, **Aimo A**, Lorenzoni V, Caselli C, Gimelli A. Triglyceride-glucose index predicts outcome in patients with chronic coronary syndrome independently of other risk factors and myocardial ischaemia. *Eur Heart J Open.* 2021;1:oeab004.

Clerico A, **Aimo A**, Zaninotto M, Plebani M. Diagnostic algorithms for non-ST-segment elevation myocardial infarction: open issues. *Clin Chem Lab Med.* 2021;59:1761-1771.

Katsi V, Georgiopoulos G, Mitropoulou P, ...**Aimo A**, et al. Exercise tolerance and quality of life in patients with known or suspected coronary artery disease. *Qual Life Res.* 2021;30:2541-2550.

Niccoli G, Morrone D, De Rosa S, ... **Aimo A**, et al. The central role of invasive functional coronary assessment for patients with ischemic heart disease. *Int J Cardiol.* 2021;331:17-25.

Aimo A, Pascual-Figal DA, Barison A, et al. Colchicine for the treatment of coronary artery disease. *Trends Cardiovasc Med.* 2020:S1050-1738(20)30130-4.

Aimo A, Pascual Figal DA, Bayes-Genis A, Emdin M, Georgiopoulos G. Effect of low-dose colchicine in acute and chronic coronary

syndromes: A systematic review and meta-analysis. *Eur J Clin Invest.* 2021;51:e13464.

Aimo A, Iborra-Egea O, Martini N, et al. Cardiac protection by pirfenidone after myocardial infarction: a bioinformatic analysis. *Sci Rep.* 2022;12:4691.

Aimo A, Spitaleri G, Nieri D, Tavanti LM, Meschi C, Panichella G, Lupón J, Pistelli F, Carrozzi L, Bayes-Genis A, Emdin M. Pirfenidone for idiopathic pulmonary fibrosis and beyond. *Card Fail Rev.* 2022;8:e12.

Aimo A, Cerbai E, Bartolucci G, et al. Pirfenidone is a cardioprotective drug: Mechanisms of action and preclinical evidence. *Pharmacol Res.* 2020;155:104694.

Aimo A, Spitaleri G, Panichella G, et al. Pirfenidone as a novel cardiac protective treatment. *Heart Fail Rev.* 2022;27:525-532.

Aimo A, Emdin M, Passino C. Intracoronary delivery of mitochondria to prevent ischemia-reperfusion injury: the challenging pathway from bench to bedside. *JACC Basic to Translational Science.* 2020;5:208.

Aimo A, De Caterina R. Aspirin for primary cardiovascular prevention: why the wonder drug should not be precipitously dismissed. *Pol Arch Intern Med.* 2020;130:121-129.

Aimo A, De Caterina R. Aspirin for primary cardiovascular prevention: advice for a decisional strategy still based on risk stratification. *Anatol J Cardiol.* 2020;23:70-78.

De Caterina R, **Aimo A**, Ridker PM. Aspirin therapy for primary prevention: the case for continuing prescribing to patients at high cardiovascular risk-a review. *Thromb Haemost.* 2020;120:199-206.

Aimo A, De Caterina R. Aspirin for primary cardiovascular prevention: is there a need for risk stratification? *Eur Heart J.* 2019;40:2922-2923.

Aimo A, Botto N, Vittorini S, Emdin M. Polymorphisms in the eNOS gene and the risk of coronary artery disease: Making the case for genome-wide association studies. *Eur J Prev Cardiol.* 2018:2047487318797402.

Pastormerlo LE, **Aimo A**, Piepoli M, Emdin M. The bottleneck of cardiac rehabilitation for patients with coronary artery disease: How to overcome. *Eur J Prev Cardiol.* 2018:2047487318785001.

Aimo A, Migliorini P, Vergaro G, et al. The IL-33/ST2 pathway, inflammation and atherosclerosis: Trigger and target? *Int J Cardiol.* 2018;267:188-192.

Aimo A, Borrelli C, Giannoni A, et al. Cardioprotection by remote ischemic conditioning: Mechanisms and clinical evidence. *World J Cardiol.* 2015;7:621-32.

Miscellanea

Clerico A, Zaninotto M, **Aimo A**, et al. Evaluation of the cardiovascular risk in patients undergoing major non-cardiac surgery: role of cardiac-specific biomarkers. *Clin Chem Lab Med.* 2022;60:1525-1542.

Bayés-Genís A, **Aimo A**, Lupón J. Endomyocardial biopsy in myocarditis: need for proper tissue characterization to keep it alive and kicking. *Rev Esp Cardiol (Engl Ed).* 2022;S1885-5857(22)00121-9.

Quattrone F, **Aimo A**, Castiglione V, et al. Using co-creation to develop a cardiology online open course: an effective approach for implementing digital learning. *J Cardiovasc Med (Hagerstown)*. 2022;23:481-483.

Perrone MA, **Aimo A**, Bernardini S, Clerico A. Natriuretic peptides and troponins to predict cardiovascular events in patients undergoing major non-cardiac surgery. *Int J Environ Res Public Health*. 2022;19:5182.

Franco AD, Morfino P, **Aimo A**. Plasma acylcarnitine, risk for heart failure or atrial fibrillation, and effects of the Mediterranean diet or obesity. *Rev Esp Cardiol (Engl Ed)*. 2022;75:621-622.

Aimo A, Chiappino S, Paolicchi A, et al. Big gamma-glutamyltransferase is associated with epicardial fat volume and cardiovascular outcome in the general population. *Eur J Prev Cardiol*. 2021;zwab215.

Saccaro LF, **Aimo A**, Emdin M, Pico F. Remote ischemic conditioning in ischemic stroke and myocardial infarction: similarities and differences. *Front Neurol*. 2021;12:716316.

Georgiopoulos G, Ntritsos G, Stamatelopoulos K, ... **Aimo A**, et al. The relationship between blood pressure and risk of atrial fibrillation: a Mendelian randomization study. *Eur J Prev Cardiol*. 2021:zwab005.

Aimo A, Manetti S, Emdin M. How much is it to mend a broken heart? Results from the US Nationwide Readmission Database. *Int J Cardiol*. 2021;329:150-151.

Clerico A, **Aimo A**, Cantinotti M. Cardiac biomarkers for outcome prediction in infant bronchiolitis: Too soon to discard troponin? *Clin Chim Acta*. 2021:S0009-8981(21)00120-0.

Clerico A, **Aimo A**, Cantinotti M. High-sensitivity cardiac troponins in pediatric population. Clin Chem Lab Med. 2021 Oct 22. doi: 10.1515/cclm-2021-0976.

Petricciuolo S, Delle Donne MG, **Aimo A**, et al. Pre-treatment high-sensitivity troponin T for the short-term prediction of cardiac outcomes in patients on immune checkpoint inhibitors. Eur J Clin Invest. 2021;51:e13400.

Castiello T, Georgiopoulos G, ...**Aimo A**, et al. COVID-19 and myocarditis: a systematic review and overview of current challenges. Heart Fail Rev. 2021:1–11.

Figliozzi S, Masci PG, Ahmadi N, ...**Aimo A**, et al. Predictors of adverse prognosis in COVID-19: A systematic review and meta-analysis. Eur J Clin Invest. 2020;50:e13362.

Gentile F, **Aimo A**, Forfori F, et al. COVID-19 and risk of pulmonary fibrosis: the importance of planning ahead. Eur J Prev Cardiol. 2020;27:1442-1446.

Castaldo N, **Aimo A**, Castiglione V, et al. Safety and efficacy of amiodarone in a patient with COVID-19. JACC Case Rep. 2020;2:1307-1310.

Barison A, **Aimo A**, Castiglione V, et al. Cardiovascular disease and COVID-19: les liaisons dangereuses. Eur J Prev Cardiol. 2020;27:1017-1025.

Aimo A, Baritussio A, Emdin M, Tascini C. Amiodarone as a possible therapy for coronavirus infection. Eur J Prev Cardiol. 2020 Apr 16:2047487320919233. Epub ahead of print.

Aimo A, Emdin M, De Caterina R. Low-thrombogenicity mechanical heart valves: which antithrombotic strategy? *JACC*. 2018;72:1878-1879.

Aimo A, Giugliano RP, De Caterina R. Non-vitamin K antagonist oral anticoagulants for mechanical heart valves. *Circulation*. 2018;138:1356-1365.

Petricciuolo S, **Aimo A**, De Caterina R. Prevenzione dell'ictus nel paziente con fibrillazione atriale e malattia renale cronica stadio 4 o in terapia dialitica [article in Italian]. *G It Cardiol*. 2020;21:6-15.

Tascini C, **Aimo A**, Arzilli C, et al. Procalcitonin, white blood cell count and C-reactive protein as predictors of *S. aureus* infection and mortality in infective endocarditis. *Int J Cardiol*. 2020;301:190-194.

Pallotto C, Sbrana F, Ripoli A, ...**Aimo A**, et al. Daptomycin-based aminoglycoside-sparing therapy for streptococcal endocarditis: a retrospective multicenter study. *J Chemother*. 2021;33:435-439.

Aimo A, Giannoni A, Vergaro G, Emdin M. Longer sleep duration and poor sleep quality as risk factors for hyperlipidaemia. *Eur J Prev Cardiol*. 2019;26:1285-1287.

Passino C, **Aimo A**, Masotti S, et al. Cardiac troponins as biomarkers for cardiac disease. *Biomark Med*. 2019;13:325-330.

Nardi C, **Aimo A**, Bortolotti U. L'ecocardiografia transtoracica nella valutazione preoperatoria dell'insufficienza mitralica degenerativa [article in Italian]. *Cardiologia Ambulatoriale*. 2018;2:118-121.

Barbiero S, **Aimo A**, Castiglione V, et al. Healthy hearts at hectic pace: From daily life stress to abnormal cardiomyocyte function and arrhythmias. *Eur J Prev Cardiol*. 2018;25:1419-1430.

Di Paolo M, **Aimo A**, Barison A, et al. The heart after idarubicin overdose. Cardiac death in a patient with acute promyelocytic leukaemia. *Int J Cardiol.* 2016;203:997-999.

Book chapters

Restrictive cardiomyopathies.

ESC Textbook on Heart Failure. Section: Aetiology of Heart Failure. Oxford Medicine (new edition).

Hypertension and heart failure (2nd edition)

Chapter 16. Left ventricular diastolic dysfunction

Springer editor, publication 2022.

Ischemic heart disease: from diagnosis to treatment.

Chapter 1: Surgical anatomy of coronary arteries: morphogenesis, normal and pathological anatomy

Springer editor, publication 2022.

Encyclopedia of Nuclear Medicine and Molecular Imaging

Chapter: Myocardial innervation imaging: ¹²³I-MIBG planar scintigraphy and SPECT

Publication 2021.

Amiloidosi cardiaca: come si diagnostica, come si cura.

Editors: Michele Emdin, Giuseppe Vergaro, Claudio Passino.

Chapters: Breve storia delle amiloidosi; La malattia da deposizione di catene leggere; uno scompenso di cuore senza amiloide; *Red flags* per il sospetto di amiloidosi cardiaca; Terapia farmacologica dell'amiloidosi da transtiretina.

Pisa University Press, 2020.

The Rediscovered Tricuspid Valve: Structure, Function and Clinical Significance in Health and Disease.

	<p>Editor: Giacomo Bianchi. Chapter 12 (Pharmacological Treatment of Tricuspid Regurgitation. A disease-modifying approach or procrastination to structural treatment?). Nova Publishers, 2019.</p> <p>Thyroid and the heart. Editors: Giorgio Iervasi, Alessandro Pingitore. Chapter 24 (Thyroid, Heart Failure and Neuroendocrine Activation). Springer Ed., 2019.</p> <p>Mario Meola. Echography in Nephrology. Chapters 31 (Ultrasonographic assessment of epiaortic vessels) and 32 (Ultrasonographic assessment of lower limb arteries). Springer Ed., 2019.</p> <p>The Breathless Heart. Apneas and the Failing Heart. Editors: Michele Emdin, Alberto Giannoni, Claudio Passino. Chapters 1 (Historical background and glossary of the apnea phenomenon), 5 (The importance of visceral feed-backs: focus on chemoreceptors), 10 (Diagnostic tools: the easier, the better), 12 (Targeting and Treating Apneas). Springer Ed., 2017</p>
Abstracts	<p>Author of over 130 abstracts presented at national and international meetings.</p>
Memberships	<ul style="list-style-type: none"> - Fellow of the Heart Failure Association of the ESC - ESC professional membership - HoT (Heart Failure Specialists of Tomorrow), ICOT (Italian Cardiologists of Tomorrow) - ESC Working groups on Myocardial & Pericardial Diseases, Cardiovascular Pharmacotherapy, Myocardial Function - ESC HFA Working groups on Imaging and Atrial Disease - European Association of Cardiovascular Imaging - Society for Cardiovascular Magnetic Resonance

	<ul style="list-style-type: none"> - American Society of Nuclear Cardiology - International Society of Amyloidosis - Italian Society of Amyloidosis - Società Italiana di Cardiologia (SIC) - Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) - Società Italiana di Biochimica Clinica e Biologia Molecolare Clinica - European Ligand Assay Society (ELAS)
Teaching activity	<ul style="list-style-type: none"> - “Rising Hearts” project (updates on recent literature on ATTR cardiomyopathy for Pfizer specialists), 2022 - Masters course on “Pathophysiology and management of heart failure”, Scuola Superiore Sant’Anna, Pisa (2019 and 2021 editions) - Supervisor of three theses (Dr. Eleonora Benelli, April 2021; Dr. Agnese Maccarana, December 2021; Dr. Lucio Teresi, to be discussed in December 2022) - Italian Certification for tenured Associate Professorship in Biochemistry and Clinical Chemistry
Editor activity	<p>Associate Editor, ESC Heart Failure</p> <p>Associate Editor, European Journal of Heart Failure (upcoming)</p> <p>Academic Editor, PlosOne</p> <p>International Associate Editor, Imaging</p> <p>Editorial Consultant, JACC Case Report</p> <p>Associate Editor, Frontiers in Cardiovascular Medicine</p> <p>Associate Editor, International Journal of Cardiology</p> <p>Associate Editor, Journal of Cardiovascular Medicine</p>
Reviewer activity	<p>Lancet, Journal of the American College of Cardiology (JACC), JACC Heart Failure, JACC Basic to Translational Science, JACC Case Reports, Circulation Heart Failure, European Heart Journal (EHJ), EHJ Case Report, European Journal of Heart Failure, European Journal of Preventive Cardiology, International Journal of Cardiology (IJC), IJC Heart & Vasculature, Journal of the American Society of Echocardiography, Annals of Laboratory Medicine, PlosOne, Journal of Heart and Lung Transplantation, Clinica Chimica Acta, Nature Scientific Report, Gene Therapy, Cardiovascular Diabetology, Kidney</p>

	<p>International, Journal of Cardiovascular Medicine, BMJ Open, BMC Cardiovascular Disorders, BMC Geriatrics, Medical Science Monitor Basic Research, Bioscience Reports, Expert Review of Cardiovascular Therapy, Advances in Clinical Chemistry, Biomarkers in Medicine, Journal of Cardiovascular Medicine, Indian Heart Journal, Frontiers in Cardiovascular Medicine, Parasitology Research, American Journal of Cardiovascular Drugs.</p> <p>Reviewer of research projects for:</p> <ul style="list-style-type: none"> - Czech Health Research Council - Ministry of Health of the Czech Republic (2019) - Heart Research UK (2021) - Icelandic Research Fund (2022)
<p>PI/investigator activity</p>	<ul style="list-style-type: none"> - Co-PI of the CATCH study, sponsored by Pfizer and Eidos - Co-PI of the ITALY study, sponsored by Pfizer - Site Co-PI of the study: “Global prevalence of transthyretin amyloid cardiomyopathy (ATTR-CM) in participants with heart failure with preserved ejection fraction (HFpEF)” sponsored by Pfizer - Site investigator for the ATTRIBUTE-CM trial (Eidos Therapeutics) and the B3461087 study (Pfizer) - Site investigator for the CARDIO-TTRansform trial (Ionis Pharmaceuticals, Inc.)
<p>Prizes and grants</p>	<ul style="list-style-type: none"> - Premio Fausto Rovelli 2022 (biomarkers for the diagnosis of cardiac amyloidosis) - “Talento Plus” (award for best PhD program): 1,333 € - Training grant from Pfizer for the project “Multimodality imaging for the diagnosis and management of cardiac transthyretin with a focus on nuclear techniques”: 100,000 \$ - Grants from Pfizer and Eidos Therapeutics for the CATCH study: 175,000 \$ - Pfizer grant for the study “Patient-Reported Outcome Measures in Wild-Type and Variant Cardiac Transthyretin Amyloidosis: The ITALY (Impact of Transthyretin Amyloidosis on Life quality) Study”: 250,000 €.

	<ul style="list-style-type: none"> - Tuscany research grants for sudden cardiac death in the young: 475,000 €. - TalentItaly (national competition for initiatives in interactive medical education): 1st prize for the project “The symptoms of the heart”, 100,000 €. - Best publication award of the Italian Society of Cardiology (2019). - Young Researcher award, ANMCO 2018. - Top Reviewer of the International Journal of Cardiology for the year 2017. - “Diastole Diseased” Congress, Fondazione Internazionale Menarini, Pisa, March 2016. Young Investigator Award.
Research fellowships	<p>Research fellow at the Institut del Cor, Hospital Universitari Germans Trial I Pujol Period: February-July 2022 Supervisor: Antoni Bayes-Genis Main topic: ventricular remodelling after myocardial infarction and in heart failure.</p> <p>Research fellow at the Massachusetts General Hospital – Boston. Period: August-September 2016. Supervisor: James L Januzzi. Main topic: biomarkers of reverse remodeling.</p> <p>Visiting student at the Columbia University Medical Center, H. Houston Merritt Clinical Research Center – New York City. Period: August-September 2014 Supervisors: Salvatore DiMauro, Michio Hirano Main topic: mitochondrial cardiomyopathy.</p> <p>Visiting student at the Icahn School of Medicine at Mount Sinai, Cardiovascular Research Center – New York. Period: August-September 2013 Supervisor: Roger Hajjar</p>

Main topics: characterization of iPSC-derived cardiomyocytes with mutated phospholamban; correction of the gene mutation through the restriction endonuclease TALEN.

Tutto quanto dichiarato corrisponde a verità ai sensi delle norme in materia di dichiarazioni sostitutive di cui all'art. 46 e ss. del D.P.R. 445/2000

Pisa (Italy), November 29, 2022

